Nanomaterial-Based Modulation of Tumor Microenvironments for Enhancing Chemo/Immunotherapy
- PMID: 31102154
- DOI: 10.1208/s12248-019-0333-y
Nanomaterial-Based Modulation of Tumor Microenvironments for Enhancing Chemo/Immunotherapy
Abstract
The tumor microenvironment (TME) has drawn considerable research attention as an alternative target for nanomedicine-based cancer therapy. Various nanomaterials that carry active substances have been designed to alter the features or composition of the TME and thereby improve the delivery and efficacy of anticancer chemotherapeutics. These alterations include disruption of the extracellular matrix and tumor vascular systems to promote perfusion or modulate hypoxia. Nanomaterials have also been used to modulate the immunological microenvironment of tumors. In this context, nanomaterials have been shown to alter populations of cancer-associated fibroblasts, tumor-associated macrophages, regulatory T cells, and myeloid-derived suppressor cells. Despite considerable progress, nanomaterial-based TME modulation must overcome several limitations before this strategy can be translated to clinical trials, including issues related to limited tumor tissue penetration, tumor heterogeneity, and immune toxicity. In this review, we summarize recent progress and challenges of nanomaterials used to modulate the TME to enhance the efficacy of anticancer chemotherapy and immunotherapy.
Keywords: chemotherapy; immunotherapy; modulation of microenvironment; nanomaterials; tumor microenvironment.
Similar articles
-
Modulation of tumor microenvironment for immunotherapy: focus on nanomaterial-based strategies.Theranostics. 2020 Feb 10;10(7):3099-3117. doi: 10.7150/thno.42998. eCollection 2020. Theranostics. 2020. PMID: 32194857 Free PMC article. Review.
-
Combining Nanomedicine and Immunotherapy.Acc Chem Res. 2019 Jun 18;52(6):1543-1554. doi: 10.1021/acs.accounts.9b00148. Epub 2019 May 23. Acc Chem Res. 2019. PMID: 31120725 Free PMC article.
-
Hypoxia-modulatory nanomaterials to relieve tumor hypoxic microenvironment and enhance immunotherapy: Where do we stand?Acta Biomater. 2021 Apr 15;125:1-28. doi: 10.1016/j.actbio.2021.02.030. Epub 2021 Feb 24. Acta Biomater. 2021. PMID: 33639310 Review.
-
Recent progress in nanomaterials for nucleic acid delivery in cancer immunotherapy.Biomater Sci. 2019 Jun 25;7(7):2640-2651. doi: 10.1039/c9bm00214f. Biomater Sci. 2019. PMID: 31090764 Review.
-
Nanomaterials in modulating tumor-associated macrophages and enhancing immunotherapy.J Mater Chem B. 2024 May 22;12(20):4809-4823. doi: 10.1039/d4tb00230j. J Mater Chem B. 2024. PMID: 38695349 Review.
Cited by
-
Biorobotic Drug Delivery for Biomedical Applications.Molecules. 2024 Aug 2;29(15):3663. doi: 10.3390/molecules29153663. Molecules. 2024. PMID: 39125066 Free PMC article. Review.
-
Nanomaterials in tumor immunotherapy: new strategies and challenges.Mol Cancer. 2023 Jun 13;22(1):94. doi: 10.1186/s12943-023-01797-9. Mol Cancer. 2023. PMID: 37312116 Free PMC article. Review.
-
Tumor Microenvironment Regulation and Cancer Targeting Therapy Based on Nanoparticles.J Funct Biomater. 2023 Feb 28;14(3):136. doi: 10.3390/jfb14030136. J Funct Biomater. 2023. PMID: 36976060 Free PMC article. Review.
-
Biodegradable MnO2-based gene-engineered nanocomposites for chemodynamic therapy and enhanced antitumor immunity.Mater Today Bio. 2022 Dec 28;18:100531. doi: 10.1016/j.mtbio.2022.100531. eCollection 2023 Feb. Mater Today Bio. 2022. PMID: 36619204 Free PMC article.
-
Lipid nanoparticle-mediated CRISPR/Cas9 gene editing and metabolic engineering for anticancer immunotherapy.Asian J Pharm Sci. 2022 Aug;17(5):641-652. doi: 10.1016/j.ajps.2022.07.005. Epub 2022 Aug 22. Asian J Pharm Sci. 2022. PMID: 36382304 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources